Asset
Treprostinil Diolamine
United Therapeutics Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01104870 | phase2 | completed | 2010-04-01 | 2013-01-01 | United Therapeutics | A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension |
| NCT01560637 | phase3 | completed | 2013-09-11 | 2021-08-12 | United Therapeutics | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension |
| NCT00760916 | phase3 | withdrawn | 2008-12-01 | 2009-01-01 | United Therapeutics | FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) |
| NCT02318758 | phase1 | completed | 2014-09-01 | 2014-10-01 | United Therapeutics | Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers |
| NCT01560624 | phase3 | completed | 2012-06-26 | 2018-06-24 | United Therapeutics | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 203496 | NDA | UNITED THERAPEUTICS CORP |
Marketed products (5)
- ORENITRAM
- ORENITRAM
- ORENITRAM
- ORENITRAM
- ORENITRAM